Pfizer-Wyeth Merger Set To Transform China’s Pharmaceutical Industry
This article was originally published in PharmAsia News
Executive Summary
After Pfizer's announced intention to acquire Wyeth, informed sources reveal that both firms' business and personnel changes in China will start this Q4. Pfizer said the move will strengthen its business and brand name as well as cut expenses. However, nothing is mentioned about the fate of Wyeth's nutritional products - especially milk powder - that make up its main income in the country. Analysts think the merger will not directly impact the local industry since 97 percent of domestic products comprise generic drugs different from Pfizer's product lines. In the short term, these firms can look forward to cloning the giant's about-to-expire patent drugs. Even so, a growing Pfizer will force the local pharmaceutical industry to upgrade and transform itself in the long run. (Click here for more - Chinese language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.